TCGA-BH-A0B9-01A-11R-A056-07
— · E
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- E
- subtype
- E
- overall_survival_months
- 52
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V2+0.570
- E2F_TARGETS+0.530
- ALLOGRAFT_REJECTION+0.510
- MYC_TARGETS_V1+0.490
- G2M_CHECKPOINT+0.380
- INTERFERON_GAMMA_RESPONSE+0.260
- INTERFERON_ALPHA_RESPONSE+0.240
- KRAS_SIGNALING_DN+0.210
- SPERMATOGENESIS+0.210
- MTORC1_SIGNALING+0.160
Top 10 suppressed
- ANGIOGENESIS-0.510
- TGF_BETA_SIGNALING-0.490
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.460
- UV_RESPONSE_DN-0.420
- ESTROGEN_RESPONSE_EARLY-0.390
- PROTEIN_SECRETION-0.370
- ANDROGEN_RESPONSE-0.360
- HEDGEHOG_SIGNALING-0.320
- ESTROGEN_RESPONSE_LATE-0.290
- APOPTOSIS-0.280
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-OL-A5D7-01A-11R-A27Q-07 | — | E | 0.876 |
| 2 | 412859bb-8b2a-44bf-b3b2-6acd30986067 | — | — | 0.871 |
| 3 | TCGA-NC-A5HL-01A-11R-A26W-07 | — | cohortSQ2 | 0.868 |
| 4 | MBCproject_0095_T3_RNA | — | E | 0.868 |
| 5 | SRR1313149 | — | D | 0.861 |
| 6 | SRR10900596 | — | — | 0.855 |
| 7 | SRR8518297 | — | E | 0.855 |
| 8 | BS_MMNRZ1EQ | ATRT | — | 0.852 |
| 9 | SRR11296816 | — | — | 0.850 |
| 10 | TCGA-E2-A1LI-01A-12R-A157-07 | — | E | 0.850 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 17 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V2 | 0.570 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.530 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.510 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.490 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.380 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.260 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.240 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.210 | Remibrutinib | — uncovered |
| SPERMATOGENESIS | 0.210 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.160 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.140 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.140 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.140 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.070 | Idelalisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.060 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.010 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.010 | Idelalisib | — uncovered |